U.S. Peripheral Vascular Angiography Contrast Media Market

U.S. Peripheral Vascular Angiography Contrast Media Market Size Insights Forecasts to 2035

• U.S. Peripheral Vascular Angiography Contrast Media Market Size 2024: USD 242.7 Mn
• U.S. Peripheral Vascular Angiography Contrast Media Market Size 2035: USD 542.16 Mn
• U.S. Peripheral Vascular Angiography Contrast Media Market CAGR 2024: 7.58%
• U.S. Peripheral Vascular Angiography Contrast Media Market Segments: Modality, Product, and End Use8

The U.S. Peripheral Vascular Angiography Contrast Media Market Size consists of such contrast agents that are specially designed to provide clear visualization of the peripheral blood vessels during both diagnostic and interventional angiographic procedures. These contrast media are significantly employed across ultrasound, CT/X, ray, and MRI modalities to facilitate precise diagnosis, procedural planning, and treatment of peripheral vascular disorders in the United States. The expansion of this market is enabled by the increasing occurrence of peripheral artery disease, diabetes, and cardiovascular conditions, as well as the growing adoption of image, guided diagnostic and interventional procedures.

 

This market is also supported by well, developed healthcare infrastructure, high volumes of diagnostic imaging, and constant innovations in contrast formulations. The transition to low, osmolar iodinated agents, better gadolinium, based products, and microbubble contrast technologies is not only elevating the imaging quality but also making it safer for the patients. Besides, the increasing trend of minimally invasive vascular procedures and outpatient diagnostic imaging is benefiting the utilization of contrast media in U.S. healthcare facilities, which is, in turn, leading to their growth.

 

Market Dynamics of the U.S. Peripheral Vascular Angiography Contrast Media Market:

The market is primarily fueled by the increased use of image, guided diagnostic and interventional vascular procedures, a rising need for accurate vascular imaging, and unceasing advancements in contrast agent technology. Besides, the elevated emphasis on the early diagnosis and minimally invasive treatment methods, among others, contributes to the escalation in the consumption of angiography contrast media in healthcare settings.

 

The rise in the market is limited by the existence of issues like the possibility of contrast, induced adverse reactions, compliance with regulatory requirements, and the necessity for a cautious use of patients with renal impairment. Moreover, there might be a limitation in the rapid introduction of new products because of strict approval procedures and high development costs.

 

By developing safer contrast agents, innovating in microbubble and low, toxicity formulations, and incorporating contrast media with advanced imaging platforms, there will be significant prospects for the future. Additionally, the growth in outpatient imaging services and the research for the next, generation contrast technologies will be the main drivers for the market in the long run.

 

Market Segmentation

The U.S. Peripheral Vascular Angiography Contrast Media Market share is classified into modality, product, and end use.

By Modality:

The U.S. peripheral vascular angiography contrast media market is divided by modality into ultrasound, magnetic resonance imaging (MRI), and CT/X-ray. Among these, the CT/X-ray segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The growth in this segment is primarily attributable to the increased use of CT/X, ray angiography for a quick peripheral vascular assessment in emergency and interventional departments. The short time of the procedure, the high spatial resolution, and the applicability for complex vascular mapping are the factors that increase the demand for the modality, specific without the need for product or end, use factors.

 

By Product:

The U.S. peripheral vascular angiography contrast media market is divided by product into iodinated, microbubble, and gadolinium-based contrast media. Among these, the iodinated segment dominated the share in 2024 and is anticipated to grow at a notable CAGR during the forecast period. This segment perpetuates its growth by continuous product refinement mainly aimed at reduced nephrotoxicity, improved hemodynamic tolerance, and enhanced contrast efficiency. Besides, the regulatory approvals of safer formulations and the strong physician's trust in the well, known chemical profiles are the factors that support the repeat usage which is independent of any modality expansion or hospital volume trends.

 

By End Use:

The U.S. peripheral vascular angiography contrast media market is divided by end use into hospitals, diagnostic imaging centres, and others. Among these, the hospitals segment dominated the share in 2024 and is anticipated to grow at a notable CAGR during the forecast period.  Such an expansion is upheld by the major structural healthcare changes that are centralizing vascular care delivery. Therefore, hospitals are the ones who are managing complex peripheral interventions that need multidisciplinary teams, post, procedure monitoring, and reimbursement, linked imaging protocols which result in them driving a higher contrast media consumption as compared to ambulatory or outpatient settings.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the U.S. peripheral vascular angiography contrast media market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

Top Key Companies in U.S. Peripheral Vascular Angiography Contrast Media Market:

• Guerbet
• Bracco
• Bayer
• GE HealthCare
• Fresenius Kabi USA
• Lantheus Holdings, Inc.

 

Recent Developments in U.S. peripheral vascular angiography contrast media market:

In November 2025, Amneal Pharmaceuticals got a nod from the U.S. FDA for its iohexol injection, a first generic version of GE HealthCare's Omnipaque radiographic contrast agent used in peripheral and body imaging procedures. The approval will probably lead to less congestion, better access, and support the use of contrast media at a reasonable price in diagnostic and interventional vascular imaging in healthcare facilities all over the U.S.

 

In September 2022, the United States Food and Drug Administration gave the green light to Elucirem (gadopiclenol), which is a macrocyclic gadoliniumbased MRI contrast agent with higher relaxivity that brightens the image quality with less gadolinium dose. The approval helps the visualization of the vascular and softtissue by the MRI method and thus more physicians will safely use this solution for peripheral and body imaging.

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Market Segment

This study forecasts revenue at the U.S., regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the U.S. peripheral vascular angiography contrast media market based on the below-mentioned segments:

 

U.S. Peripheral Vascular Angiography Contrast Media Market, By Modality

• Ultrasound
• Magnetic Resonance Imaging (MRI)
• CT/X-ray

 

U.S. Peripheral Vascular Angiography Contrast Media Market, By Product

• Iodinated
• Microbubble
• Gadolinium-Based

 

U.S. Peripheral Vascular Angiography Contrast Media Market, By End Use

• Hospitals
• Diagnostic Imaging Centres
• Others

 

FAQ

Q: What is the U.S. peripheral vascular angiography contrast media market size?

A: U.S. Peripheral Vascular Angiography Contrast Media Market is expected to grow from USD 242.7 million in 2024 to USD 542.16 million by 2035, growing at a CAGR of 7.58% during the forecast period 2025-2035.

 

Q: What are the key growth drivers of the market?

A: Market growth is driven by the rising prevalence of peripheral artery disease, diabetes, and cardiovascular disorders, the increasing adoption of image-guided diagnostic and interventional procedures, and innovations in safer, low-toxicity, and high-performance contrast agents for ultrasound, MRI, and CT/X-ray modalities.

 

Q: What factors restrain the U.S. peripheral vascular angiography contrast media market?

A: Market restraints include possible contrast-induced adverse reactions, regulatory compliance requirements, cautious use in patients with renal impairment, high development costs, and stringent approval procedures delaying new product launches.

 

Q: How is the market segmented by modality?

A: The market is segmented into Ultrasound, Magnetic Resonance Imaging (MRI), and CT/X-ray.

 

Q: How is the market segmented by product?

A: The market is segmented into Iodinated, Microbubble, and Gadolinium-Based contrast media.

 

Q: How is the market segmented by end use?

A: The market is segmented into Hospitals, Diagnostic Imaging Centres, and Others.

 

Q: Who are the key players in the U.S. peripheral vascular angiography contrast media market?

A: Key companies include Guerbet, Bracco, Bayer, GE HealthCare, Fresenius Kabi USA, and Lantheus Holdings, Inc.

 

Q: Who are the target audiences for this market report?

A: The report targets market players, investors, end-users, government authorities, consulting and research firms, venture capitalists, and value-added resellers (VARs).